Loading stock data…
GILD
$125.50-2.60 (-2.03%)
After Hours$125.18-0.32 (-0.26%)· Last close Jun 9
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Gilead Sciences, Inc. in the Healthcare sector is trading at $125.50. Wall Street consensus targets $157.83 (29 analysts), implying a +25.8% move over the next 12 months. The stock is currently 20% below its 52-week high of $157.29, remaining 2.1% below its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +25.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$125.50
Potential Downside
0%
Whystock Fair Value$125.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus29 analysts
Buy
Mean target$157.83+25.8%
Range$122.00 – $180.00
Fundamentals
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.54%
ROE
Elite ROE. Management converts capital into profit efficiently.
39.19%
Volume
Today's trading volume
8.16M
Recent News
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus
Gilead Sciences (NasdaqGS:GILD) and Merck reported that their once weekly oral HIV regimen, islatravir and lenacapavir, met its primary endpoint in a Phase 3 trial, showing statistically non inferior efficacy to daily standard of care. The companies also stopped a Phase 3 study combining Trodelvy and KEYTRUDA in advanced lung cancer after the treatment did not deliver a statistically significant improvement in progression free survival. These mixed trial outcomes arrive with Gilead Sciences...
Stocks Climb on an AI-Led Rebound
The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
Will HIV Win and Lung Cancer Loss in Trials Recast Merck’s (MRK) Risk Reward Narrative?
In early June 2026, Gilead Sciences and Merck reported that their investigational once-weekly oral HIV regimen of islatravir/lenacapavir met the primary efficacy endpoint and showed a comparable safety profile to standard daily treatments in two Phase 3 ISLEND trials, and they plan global regulatory filings based on these data. At the same time, Merck and Gilead halted a Phase 3 lung cancer study combining Trodelvy with KEYTRUDA after it failed to show a statistically significant...